Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease
Identifieur interne : 001543 ( Main/Corpus ); précédent : 001542; suivant : 001544Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease
Auteurs : Atbin Djamshidian ; Ashwani Jha ; Sean S. O'Sullivan ; Laura Silveira-Moriyama ; Clare Jacobson ; Peter Brown ; Andrew Lees ; Bruno B. AverbeckSource :
- Movement Disorders [ 0885-3185 ] ; 2010-10-15.
English descriptors
Abstract
Relatively little is known about the interaction between behavioral changes, medication, and cognitive function in Parkinson's disease (PD). We examined working memory, learning and risk aversion in PD patients with and without impulsive or compulsive behavior (ICB) and compared the results with those in a group of age‐matched control subjects. Parkinson patients with PD+ICB had poorer working memory performance than either controls or PD patients without ICB. PD+ICB patients also showed decreased learning from negative feedback and increased learning from positive feedback in off compared with on dopaminergic medication. This interaction between medication status and learning was the opposite of that found in the PD patients without a diagnosis of ICB. Finally, the PD group showed increased risk preference on medication relative to controls, and the subgroup of PD+ICB patients with pathological gambling were overall more risk prone than the PD group. Thus, medication status and an impulsive behavioral diagnosis differentially affect several behaviors in PD. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23247
Links to Exploration step
ISTEX:4044E0EB6A5D824E78BF1649578E35EB5B89A985Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease</title><author><name sortKey="Djamshidian, Atbin" sort="Djamshidian, Atbin" uniqKey="Djamshidian A" first="Atbin" last="Djamshidian">Atbin Djamshidian</name><affiliation><mods:affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>2nd Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Jha, Ashwani" sort="Jha, Ashwani" uniqKey="Jha A" first="Ashwani" last="Jha">Ashwani Jha</name><affiliation><mods:affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="O Sullivan, Sean S" sort="O Sullivan, Sean S" uniqKey="O Sullivan S" first="Sean S." last="O'Sullivan">Sean S. O'Sullivan</name><affiliation><mods:affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Silveira Oriyama, Laura" sort="Silveira Oriyama, Laura" uniqKey="Silveira Oriyama L" first="Laura" last="Silveira-Moriyama">Laura Silveira-Moriyama</name><affiliation><mods:affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Jacobson, Clare" sort="Jacobson, Clare" uniqKey="Jacobson C" first="Clare" last="Jacobson">Clare Jacobson</name><affiliation><mods:affiliation>Department of Neuropsychology, Institute of Neurology, UCL, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Brown, Peter" sort="Brown, Peter" uniqKey="Brown P" first="Peter" last="Brown">Peter Brown</name><affiliation><mods:affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation><mods:affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Averbeck, Bruno B" sort="Averbeck, Bruno B" uniqKey="Averbeck B" first="Bruno B." last="Averbeck">Bruno B. Averbeck</name><affiliation><mods:affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, United Kingdom</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4044E0EB6A5D824E78BF1649578E35EB5B89A985</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23247</idno><idno type="url">https://api.istex.fr/document/4044E0EB6A5D824E78BF1649578E35EB5B89A985/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001543</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease</title><author><name sortKey="Djamshidian, Atbin" sort="Djamshidian, Atbin" uniqKey="Djamshidian A" first="Atbin" last="Djamshidian">Atbin Djamshidian</name><affiliation><mods:affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>2nd Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Jha, Ashwani" sort="Jha, Ashwani" uniqKey="Jha A" first="Ashwani" last="Jha">Ashwani Jha</name><affiliation><mods:affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="O Sullivan, Sean S" sort="O Sullivan, Sean S" uniqKey="O Sullivan S" first="Sean S." last="O'Sullivan">Sean S. O'Sullivan</name><affiliation><mods:affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Silveira Oriyama, Laura" sort="Silveira Oriyama, Laura" uniqKey="Silveira Oriyama L" first="Laura" last="Silveira-Moriyama">Laura Silveira-Moriyama</name><affiliation><mods:affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Jacobson, Clare" sort="Jacobson, Clare" uniqKey="Jacobson C" first="Clare" last="Jacobson">Clare Jacobson</name><affiliation><mods:affiliation>Department of Neuropsychology, Institute of Neurology, UCL, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Brown, Peter" sort="Brown, Peter" uniqKey="Brown P" first="Peter" last="Brown">Peter Brown</name><affiliation><mods:affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation><mods:affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Averbeck, Bruno B" sort="Averbeck, Bruno B" uniqKey="Averbeck B" first="Bruno B." last="Averbeck">Bruno B. Averbeck</name><affiliation><mods:affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, United Kingdom</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-10-15">2010-10-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="2203">2203</biblScope><biblScope unit="page" to="2210">2210</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">4044E0EB6A5D824E78BF1649578E35EB5B89A985</idno><idno type="DOI">10.1002/mds.23247</idno><idno type="ArticleID">MDS23247</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>impulse control disorder</term><term>memory</term><term>risk and learning</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Relatively little is known about the interaction between behavioral changes, medication, and cognitive function in Parkinson's disease (PD). We examined working memory, learning and risk aversion in PD patients with and without impulsive or compulsive behavior (ICB) and compared the results with those in a group of age‐matched control subjects. Parkinson patients with PD+ICB had poorer working memory performance than either controls or PD patients without ICB. PD+ICB patients also showed decreased learning from negative feedback and increased learning from positive feedback in off compared with on dopaminergic medication. This interaction between medication status and learning was the opposite of that found in the PD patients without a diagnosis of ICB. Finally, the PD group showed increased risk preference on medication relative to controls, and the subgroup of PD+ICB patients with pathological gambling were overall more risk prone than the PD group. Thus, medication status and an impulsive behavioral diagnosis differentially affect several behaviors in PD. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Atbin Djamshidian MD</name><affiliations><json:string>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</json:string><json:string>2nd Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria</json:string></affiliations></json:item><json:item><name>Ashwani Jha MBChB</name><affiliations><json:string>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Sean S. O'Sullivan MRCPI</name><affiliations><json:string>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Laura Silveira‐Moriyama MD, PhD</name><affiliations><json:string>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Clare Jacobson MSc</name><affiliations><json:string>Department of Neuropsychology, Institute of Neurology, UCL, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Peter Brown MD, MRCP</name><affiliations><json:string>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Andrew Lees FMedAcadSci</name><affiliations><json:string>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Bruno B. Averbeck PhD</name><affiliations><json:string>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, United Kingdom</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>impulse control disorder</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>risk and learning</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>memory</value></json:item></subject><articleId><json:string>MDS23247</json:string></articleId><language><json:string>eng</json:string></language><abstract>Relatively little is known about the interaction between behavioral changes, medication, and cognitive function in Parkinson's disease (PD). We examined working memory, learning and risk aversion in PD patients with and without impulsive or compulsive behavior (ICB) and compared the results with those in a group of age‐matched control subjects. Parkinson patients with PD+ICB had poorer working memory performance than either controls or PD patients without ICB. PD+ICB patients also showed decreased learning from negative feedback and increased learning from positive feedback in off compared with on dopaminergic medication. This interaction between medication status and learning was the opposite of that found in the PD patients without a diagnosis of ICB. Finally, the PD group showed increased risk preference on medication relative to controls, and the subgroup of PD+ICB patients with pathological gambling were overall more risk prone than the PD group. Thus, medication status and an impulsive behavioral diagnosis differentially affect several behaviors in PD. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>6.406</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>1107</abstractCharCount><pdfWordCount>4474</pdfWordCount><pdfCharCount>28146</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>161</abstractWordCount></qualityIndicators><title>Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>8</total><last>2210</last><first>2203</first></pages><issn><json:string>0885-3185</json:string></issn><issue>13</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.23247</json:string></doi><id>4044E0EB6A5D824E78BF1649578E35EB5B89A985</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/4044E0EB6A5D824E78BF1649578E35EB5B89A985/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/4044E0EB6A5D824E78BF1649578E35EB5B89A985/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/4044E0EB6A5D824E78BF1649578E35EB5B89A985/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: The authors declare no financial or other conflict of interest.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease</title><author><persName><forename type="first">Atbin</forename><surname>Djamshidian</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</affiliation><affiliation>2nd Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria</affiliation></author><author><persName><forename type="first">Ashwani</forename><surname>Jha</surname></persName><roleName type="degree">MBChB</roleName><affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, United Kingdom</affiliation></author><author><persName><forename type="first">Sean S.</forename><surname>O'Sullivan</surname></persName><roleName type="degree">MRCPI</roleName><affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</affiliation></author><author><persName><forename type="first">Laura</forename><surname>Silveira‐Moriyama</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</affiliation></author><author><persName><forename type="first">Clare</forename><surname>Jacobson</surname></persName><roleName type="degree">MSc</roleName><affiliation>Department of Neuropsychology, Institute of Neurology, UCL, London, United Kingdom</affiliation></author><author><persName><forename type="first">Peter</forename><surname>Brown</surname></persName><roleName type="degree">MD, MRCP</roleName><affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, United Kingdom</affiliation></author><author><persName><forename type="first">Andrew</forename><surname>Lees</surname></persName><roleName type="degree">FMedAcadSci</roleName><affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</affiliation></author><author><persName><forename type="first">Bruno B.</forename><surname>Averbeck</surname></persName><roleName type="degree">PhD</roleName><note type="correspondence"><p>Correspondence: Laboratory of Neuropsychology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892</p></note><affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, United Kingdom</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-10-15"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="2203">2203</biblScope><biblScope unit="page" to="2210">2210</biblScope></imprint></monogr><idno type="istex">4044E0EB6A5D824E78BF1649578E35EB5B89A985</idno><idno type="DOI">10.1002/mds.23247</idno><idno type="ArticleID">MDS23247</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Relatively little is known about the interaction between behavioral changes, medication, and cognitive function in Parkinson's disease (PD). We examined working memory, learning and risk aversion in PD patients with and without impulsive or compulsive behavior (ICB) and compared the results with those in a group of age‐matched control subjects. Parkinson patients with PD+ICB had poorer working memory performance than either controls or PD patients without ICB. PD+ICB patients also showed decreased learning from negative feedback and increased learning from positive feedback in off compared with on dopaminergic medication. This interaction between medication status and learning was the opposite of that found in the PD patients without a diagnosis of ICB. Finally, the PD group showed increased risk preference on medication relative to controls, and the subgroup of PD+ICB patients with pathological gambling were overall more risk prone than the PD group. Thus, medication status and an impulsive behavioral diagnosis differentially affect several behaviors in PD. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>impulse control disorder</term></item><item><term>risk and learning</term></item><item><term>memory</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-11-11">Received</change><change when="2010-04-15">Registration</change><change when="2010-10-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/4044E0EB6A5D824E78BF1649578E35EB5B89A985/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="130"><doi origin="wiley" registered="yes">10.1002/mds.v25:13</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">13</numbering></numberingGroup><coverDate startDate="2010-10-15">15 October 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="280" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23247</doi><idGroup><id type="unit" value="MDS23247"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2009-11-11"></event><event type="manuscriptRevised" date="2010-01-18"></event><event type="manuscriptAccepted" date="2010-04-15"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.5.2 mode:FullText source:FullText result:FullText" date="2011-07-06"></event><event type="publishedOnlineEarlyUnpaginated" date="2010-08-18"></event><event type="publishedOnlineFinalForm" date="2010-10-07"></event><event type="firstOnline" date="2010-08-18"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2203</numbering><numbering type="pageLast">2210</numbering></numberingGroup><correspondenceTo>Laboratory of Neuropsychology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23247.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="4"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="36"></count><count type="wordTotal" number="5186"></count></countGroup><titleGroup><title type="main" xml:lang="en">Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease<link href="#fn1"></link></title><title type="short" xml:lang="en">Learning and Risk in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Atbin</givenNames><familyName>Djamshidian</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Ashwani</givenNames><familyName>Jha</familyName><degrees>MBChB</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Sean S.</givenNames><familyName>O'Sullivan</familyName><degrees>MRCPI</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Laura</givenNames><familyName>Silveira‐Moriyama</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Clare</givenNames><familyName>Jacobson</familyName><degrees>MSc</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Peter</givenNames><familyName>Brown</familyName><degrees>MD, MRCP</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Andrew</givenNames><familyName>Lees</familyName><degrees>FMedAcadSci</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af3" corresponding="yes"><personName><givenNames>Bruno B.</givenNames><familyName>Averbeck</familyName><degrees>PhD</degrees></personName><contactDetails><email>averbeckbb@mail.nih.gov</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="AT" type="organization"><unparsedAffiliation>2nd Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="GB" type="organization"><unparsedAffiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="GB" type="organization"><unparsedAffiliation>Department of Neuropsychology, Institute of Neurology, UCL, London, United Kingdom</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">impulse control disorder</keyword><keyword xml:id="kwd3">risk and learning</keyword><keyword xml:id="kwd4">memory</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Relatively little is known about the interaction between behavioral changes, medication, and cognitive function in Parkinson's disease (PD). We examined working memory, learning and risk aversion in PD patients with and without impulsive or compulsive behavior (ICB) and compared the results with those in a group of age‐matched control subjects. Parkinson patients with PD+ICB had poorer working memory performance than either controls or PD patients without ICB. PD+ICB patients also showed decreased learning from negative feedback and increased learning from positive feedback in off compared with on dopaminergic medication. This interaction between medication status and learning was the opposite of that found in the PD patients without a diagnosis of ICB. Finally, the PD group showed increased risk preference on medication relative to controls, and the subgroup of PD+ICB patients with pathological gambling were overall more risk prone than the PD group. Thus, medication status and an impulsive behavioral diagnosis differentially affect several behaviors in PD. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: The authors declare no financial or other conflict of interest.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Learning and Risk in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Atbin</namePart><namePart type="family">Djamshidian</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</affiliation><affiliation>2nd Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ashwani</namePart><namePart type="family">Jha</namePart><namePart type="termsOfAddress">MBChB</namePart><affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sean S.</namePart><namePart type="family">O'Sullivan</namePart><namePart type="termsOfAddress">MRCPI</namePart><affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laura</namePart><namePart type="family">Silveira‐Moriyama</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Clare</namePart><namePart type="family">Jacobson</namePart><namePart type="termsOfAddress">MSc</namePart><affiliation>Department of Neuropsychology, Institute of Neurology, UCL, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Peter</namePart><namePart type="family">Brown</namePart><namePart type="termsOfAddress">MD, MRCP</namePart><affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrew</namePart><namePart type="family">Lees</namePart><namePart type="termsOfAddress">FMedAcadSci</namePart><affiliation>Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bruno B.</namePart><namePart type="family">Averbeck</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, UCL, London, United Kingdom</affiliation><description>Correspondence: Laboratory of Neuropsychology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-10-15</dateIssued><dateCaptured encoding="w3cdtf">2009-11-11</dateCaptured><dateValid encoding="w3cdtf">2010-04-15</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">4</extent><extent unit="tables">1</extent><extent unit="references">36</extent><extent unit="words">5186</extent></physicalDescription><abstract lang="en">Relatively little is known about the interaction between behavioral changes, medication, and cognitive function in Parkinson's disease (PD). We examined working memory, learning and risk aversion in PD patients with and without impulsive or compulsive behavior (ICB) and compared the results with those in a group of age‐matched control subjects. Parkinson patients with PD+ICB had poorer working memory performance than either controls or PD patients without ICB. PD+ICB patients also showed decreased learning from negative feedback and increased learning from positive feedback in off compared with on dopaminergic medication. This interaction between medication status and learning was the opposite of that found in the PD patients without a diagnosis of ICB. Finally, the PD group showed increased risk preference on medication relative to controls, and the subgroup of PD+ICB patients with pathological gambling were overall more risk prone than the PD group. Thus, medication status and an impulsive behavioral diagnosis differentially affect several behaviors in PD. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: The authors declare no financial or other conflict of interest.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>impulse control disorder</topic><topic>risk and learning</topic><topic>memory</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>13</number></detail><extent unit="pages"><start>2203</start><end>2210</end><total>8</total></extent></part></relatedItem><identifier type="istex">4044E0EB6A5D824E78BF1649578E35EB5B89A985</identifier><identifier type="DOI">10.1002/mds.23247</identifier><identifier type="ArticleID">MDS23247</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001543 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001543 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:4044E0EB6A5D824E78BF1649578E35EB5B89A985
|texte= Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |